Zydus Lifesciences has informed that it enclosed a copy of press release dated August 31, 2026, titled ‘Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH’.
The above information is a part of company’s filings submitted to BSE.